BRIEF-中国生物制药斥1.4亿元取得礼新医药4.91%股权,就LM-108在中国大陆战略合作

Reuters
20 Nov 2024

Nov 20 (路透) - Sino Biopharmaceutical Ltd :

* 与礼新医药签署股权投资及战略合作协议

* 以自筹资金入股礼新医药,并就LM-108及未来潜在的多个创新双特异性抗体或抗体偶联药物$(ADC)$在中国大陆地区达成战略合作

* LM-108是靶向CCR8的单克隆抗体

* 向礼新医药支付1.42亿元人民币,取得本次交易后礼新医药4.91%的股权

Source text: Further company coverage:

(发稿 徐凯文)

((Kaiwen.Xu@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10